Boehringer Ingelheim Selects Medidata Clinical Cloud
Boehringer Ingelheim will integrate Medidata’s study planning, data management, data analytics and RBM capabilities into multiple stages of its drug development process.
Medidata announced that Boehringer Ingelheim has selected the Medidata Clinical Cloud technology platform to support all of Boehringer Ingelheim's drug development programs. Boehringer Ingelheim will integrate Medidata’s study planning, data management, data analytics and risk-based monitoring (RBM) capabilities into multiple stages of its drug development process using Medidata Rave, Coder, Safety Gateway, Designer, Grants Manager and Insights, as well as its RBM solutions. The Medidata Clinical Cloud supports 10,000-plus clinical studies, 370,000 investigational sites and more than 2.7 million trial volunteers.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
